Full history for every metric is available with a Kvantra account
Allena Pharmaceuticals, Inc. (ALNA)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -32 | -27 | |||||
| Net profit | $m | -25 | -22 | -36 | -47 | -33 | -33 | -28 |
| EPS reported | $ | -1.03 | -0.31 | |||||
| Operating cashflow per share | $ | -1.41 | -1.41 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -1.43 | -1.43 | |||||
| Free cash flow | $m | -46 | -49 | |||||
| Net debt | $m | -29 | -7 | |||||
| Book value equity | $m | 19 | - | |||||
| Book value per share | $ | 0.58 | - | |||||
| Number of shares | m | 32.51 | 100.62 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.02 | 0.13 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.42 | -0.15 | |||||
| EV/EBITDA LTM | x | 0.32 | -0.03 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -173.18% | -1368.1% | |||||
| FCF Yield | % | -240.63% | -650.40% | |||||
| Quality | ||||||||
| ROE | % | -176.78% | -160.99% | |||||
| ROIC | % | -166.72% | -166.72% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -87.94 | -129.17 | |||||
| Net Debt/EBITDA | x | 0.92 | 0.92 | |||||
| EBIT/Net interest | x | -63.40 | -63.40 | |||||
| Net debt/market cap | % | -152.96% | -87.31% | |||||
| Net debt/Equity | x | -1.56 | - | |||||
| Gross debt/equity | x | 0.03 | - | |||||
Company overview
Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and market introduction of orally administered enzyme therapies. Operating within the United States, the firm is dedicated to addressing debilitating metabolic and renal conditions, particularly those that are rare and severe. Its primary therapeutic candidate, ALLN-346, is an innovative enzyme designed to break down urate. This treatment is specifically aimed at individuals experiencing hyperuricemia and gout, especially when these conditions coexist with advanced chronic kidney disease. Established in 2011, Allena Pharmaceuticals maintains its corporate headquarters in Newton, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Allena Pharmaceuticals, Inc. (ALNA)
Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and market introduction of orally administered enzyme therapies. Operating within the United States, the firm is dedicated to addressing debilitating metabolic and renal conditions, particularly those that are rare and severe. Its primary therapeutic candidate, ALLN-346, is an innovative enzyme designed to break down urate. This treatment is specifically aimed at individuals experiencing hyperuricemia and gout, especially when these conditions coexist with advanced chronic kidney disease. Established in 2011, Allena Pharmaceuticals maintains its corporate headquarters in Newton, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free